LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

53.05 3.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

51.05

Max

53.3

Belangrijke statistieken

By Trading Economics

Inkomsten

-16M

-184M

Verkoop

-6.1M

111M

Winstmarge

-166.199

Werknemers

725

EBITDA

-17M

-143M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+26.35% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

773M

9.8B

Vorige openingsprijs

49.66

Vorige sluitingsprijs

53.05

Nieuwssentiment

By Acuity

4%

96%

1 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 apr 2025, 09:30 UTC

Top Nieuws

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

26.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 65.06 USD  26.35%

Hoogste 82 USD

Laagste 42 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

17

Buy

1

Hold

0

Sell

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

1 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat